PRESS RELEASE:

Bausch + Lomb Signs Exclusive License Agreement with Paragon BioTeck for Phenylephrine

Recent US FDA Approval of NDA Clears the Way for Commercialization

| From
Phenylephrine

MADISON, N.J. and TIGARD, Ore., April 19, 2013 (SEND2PRESS NEWSWIRE) -- Bausch + Lomb, the global eye health company and Paragon BioTeck, Inc. today announced that the companies have entered into a license agreement for Bausch + Lomb to commercialize and distribute Paragon's phenylephrine in the United States on an exclusive basis beginning this month.

"This agreement with Paragon demonstrates Bausch + Lomb's commitment to partnering with companies with eye health products that can benefit from our commercial capabilities," said Dan Wechsler, President, Global Pharmaceuticals, Bausch + Lomb. "It is also an example of our on-going efforts to provide a comprehensive portfolio of eye health products to eye care practitioners and the patients they serve."

"We are enthusiastic about embarking on this new relationship with Bausch + Lomb, as this level of collaboration is consistent with Paragon's ongoing commitment to further develop and foster an unparalleled network of collaborative partners," said Patrick H. Witham, President & CEO, Paragon BioTeck, Inc.

About Phenylephrine Hydrochloride Ophthalmic Solution:

Phenylephrine Hydrochloride Ophthalmic Solution, USP 2.5% and 10% is an alpha-1 adrenergic receptor agonist used for dilation of the pupil due to its vasoconstrictor and mydriatic action. Phenylephrine possesses predominantly alpha-adrenergic effects. In the eye, phenylephrine acts locally as a potent vasoconstrictor and mydriatic by constricting ophthalmic blood vessels and the radial muscle of the iris.

Phenylephrine Hydrochloride Ophthalmic Solution Important Safety Information:

Phenylephrine Hydrochloride Ophthalmic Solution, USP 10% is contraindicated in patients with hypertension or thyrotoxicosis, as well as in pediatric patients under the age of one due to the increased risk of systemic toxicity. Phenylephrine Hydrochloride Ophthalmic Solution, USP 2.5% should be used in these patients. It's for topical ophthalmic use only, and not for injection.

Serious cardiovascular reactions, including ventricular arrhythmias and myocardial infarctions, some fatal and significant elevations in blood pressure have been reported. Caution is advised in pediatric patients less than five years of age, and in patients with elevated blood pressure, cardiovascular disease or hyperthyroidism. Blood pressure should be monitored in patients with cardiovascular or endocrine disease. Rebound miosis has been reported one day after instillation.

Ocular adverse reactions include eye pain and stinging on instillation, temporary blurred vision and photophobia. Cardiovascular adverse reactions include increase in blood pressure, syncope, myocardial infarction, tachycardia, arrhythmia and subarachnoid hemorrhage.

About Paragon BioTeck, Inc.:

Paragon BioTeck is a privately held ophthalmic-focused biopharmaceutical and medical device company pursuing the development and commercialization of products addressing unmet medical needs in the fight to protect and preserve eyesight. For more information on the company and its work, visit http://www.paragonbioteck.com/ .

About Bausch + Lomb:

Bausch + Lomb is a leading global eye health company that is solely focused on protecting, enhancing, and restoring people's eyesight. Our core businesses include ophthalmic pharmaceuticals, contact lenses and lens care products, and ophthalmic surgical devices and instruments. We globally develop, manufacture and market one of the most comprehensive product portfolios in our industry, which are available in more than 100 countries. Founded in 1853, our company is headquartered in Rochester, N.Y., and employs more than 11,000 people worldwide.

News Source:
MORE INFORMATION:
For more information regarding this press release, please visit:
http://www.paragonbioteck.com/
Like, Share, Save this press release:
  TWEET   SHARE   G+   PIN IT   STUMBLE   LinkedIn   Instapaper   Buffer

PERMALINK:
https://www.send2press.com/newswire/Bausch-Lomb-Signs-Exclusive-License-Agreement-with-Paragon-BioTeck-for-Phenylephrine_2013-04-0419-003.shtml
Shortlink to this press release: http://goo.gl/9uzTc
  LEGAL NOTICE AND TERMS OF USE:  
The content of the above press release was provided by the “news source” (Paragon BioTeck, Inc.) or authorized agency, who is solely responsible for its accuracy. Send2Press® is the originating wire service for this story and content is Copr. © 2013 Paragon BioTeck, Inc. with newswire version Copr. © 2013 Send2Press (a service of Neotrope). All trademarks acknowledged.

Rights granted for reproduction by any legitimate news organization. However, if news is cloned/scraped verbatim, then original attribution must be maintained with link back to this page as “original syndication source.” Resale of this content for commercial purposes is prohibited without a license. Reproduction on any site selling a competitive service is also prohibited. Information is believed accurate, as provided by news source or authorized agency, however is not guaranteed, and you assume all risk for use of any information found herein/hereupon. This work is licensed under a Creative Commons Attribution-NonCommercial 3.0 Unported License.
STORY READS for this single page only, as of Sep 28 2016:
[ count retired 8.4.16 ]


back to top
REFERENCES: Phenylephrine, Patrick H Witham, Patrick H. Witham, Paragon BioTeck Inc, ophthalmic-focused biopharmaceutical and medical device company, Phenylephrine Hydrochloride Ophthalmic Solution, Bausch+Lomb, topical ophthalmic use, Oregon business, news, press release from Paragon BioTeck, Inc., Apr 19, 2013, Drugs and Pharmaceuticals, Business, Pharma, Madison, New Jersey, Bausch + Lomb Signs Exclusive License Agreement with Paragon BioTeck for Phenylephrine